Literature DB >> 15557111

Mechanisms underlying reduced apoptosis in neonatal neutrophils.

Nazeeh Hanna1, Pedro Vasquez, Petra Pham, Diane E Heck, Jeffrey D Laskin, Debra L Laskin, Barry Weinberger.   

Abstract

Apoptosis, which leads to phagocytosis by mononuclear cells, represents the primary mechanism for removing neutrophils from inflamed tissues and minimizing injury. The present studies show that membrane phosphatidylserine turnover and permeability, as well as DNA fragmentation, were reduced in neutrophils from neonates when compared with adults. The activity of caspase 3 and expression of the proapoptotic proteins Bax, Bad, and Bak were also decreased in neonatal relative to adult neutrophils. These findings are consistent with impaired apoptosis in neonatal cells, which may contribute to prolonged inflammation in infants after oxidative stress or infection. Neutrophil apoptosis is induced by endogenous ligands such as Fas (FasL), which engage death receptors of the tumor necrosis factor/nerve growth factor superfamily, including Fas receptor (FasR). We found that expression of FasR was decreased in neonatal when compared with adult cells. Moreover, neonatal neutrophils did not undergo apoptosis in response to anti-FasR antibody and exhibited impaired chemotaxis to soluble FasL. However, in both adult and neonatal cells, p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase inhibitors blocked Fas-induced activity. These data suggest that prolonged survival of neonatal neutrophils at injured sites is due, in part, to reduced responsiveness to FasL. This may be related to decreased expression of both FasR and Bcl-2-family proteins that mediate neutrophil apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557111     DOI: 10.1203/01.PDR.0000147568.14392.F0

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  22 in total

1.  Inflammatory effects of phthalates in neonatal neutrophils.

Authors:  Anna M Vetrano; Debra L Laskin; Faith Archer; Kirin Syed; Joshua P Gray; Jeffrey D Laskin; Nkiru Nwebube; Barry Weinberger
Journal:  Pediatr Res       Date:  2010-08       Impact factor: 3.756

2.  Neonatal sepsis and neutrophil insufficiencies.

Authors:  John Nicholas Melvan; Gregory J Bagby; David A Welsh; Steve Nelson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2010-06       Impact factor: 5.311

Review 3.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 4.  Pathophysiology and treatment of septic shock in neonates.

Authors:  James L Wynn; Hector R Wong
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

Review 5.  Role of innate host defenses in susceptibility to early-onset neonatal sepsis.

Authors:  James L Wynn; Ofer Levy
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

Review 6.  Immune responses in neonates.

Authors:  Saleem Basha; Naveen Surendran; Michael Pichichero
Journal:  Expert Rev Clin Immunol       Date:  2014-08-04       Impact factor: 4.473

7.  Mechanisms mediating reduced responsiveness of neonatal neutrophils to lipoxin A4.

Authors:  Barry Weinberger; Cecile Quizon; Anna M Vetrano; Faith Archer; Jeffrey D Laskin; Debra L Laskin
Journal:  Pediatr Res       Date:  2008-10       Impact factor: 3.756

8.  Maternal and neonatal lipopolysaccharide and Fas responses are altered by antenatal risk factors for sepsis.

Authors:  E J Molloy; A J O'Neill; J J Grantham-Sloan; D W Webb; R W G Watson
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

Review 9.  Induction and termination of inflammatory signaling in group B streptococcal sepsis.

Authors:  Julia Wennekamp; Philipp Henneke
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

Review 10.  Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis.

Authors:  Joyce M Koenig; William J Keenan
Journal:  Pediatr Clin North Am       Date:  2009-06       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.